Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Authors: Fendler Annika , Shepherd Scott T. C. , Au Lewis , Wilkinson Katalin A. , Wu Mary , Byrne Fiona , Cerrone Maddalena , Schmitt Andreas M. , Joharatnam-Hogan Nalinie , Shum Benjamin , Tippu Zayd , Rzeniewicz Karolina , Boos Laura Amanda , Harvey Ruth , Carlyle Eleanor , Edmonds Kim , Del Rosario Lyra , Sarker Sarah , Lingard Karla , Mangwende Mary , Holt Lucy , Ahmod Hamid , Korteweg Justine , Foley Tara , Bazin Jessica , Gordon William , Barber Taja , Emslie-Henry Andrea , Xie Wenyi , Gerard Camille L. , Deng Daqi , Wall Emma C. , Agua-Doce Ana , Namjou Sina , Caidan Simon , Gavrielides Mike , MacRae James I. , Kelly Gavin , Peat Kema , Kelly Denise , Murra Aida , Kelly Kayleigh , O’Flaherty Molly , Dowdie Lauren , Ash Natalie , Gronthoud Firza , Shea Robyn L. , Gardner Gail , Murray Darren , Kinnaird Fiona , Cui Wanyuan , Pascual Javier , Rodney Simon , Mencel Justin , Curtis Olivia , Stephenson Clemency , Robinson Anna , Oza Bhavna , Farag Sheima , Leslie Isla , Rogiers Aljosja , Iyengar Sunil , Ethell Mark , Messiou Christina , Cunningham David , Chau Ian , Starling Naureen , Turner Nicholas , Welsh Liam , van As Nicholas , Jones Robin L. , Droney Joanne , Banerjee Susana , Tatham Kate C. , O’Brien Mary , Harrington Kevin , Bhide Shreerang , Okines Alicia , Reid Alison , Young Kate , Furness Andrew J. S. , Pickering Lisa , Swanton Charles ,   The Crick COVID-19 Consortium, Gandhi Sonia , Gamblin Steve , Bauer David L. V. , Kassiotis George , Kumar Sacheen , Yousaf Nadia , Jhanji Shaman , Nicholson Emma , Howell Michael , Walker Susanna , Wilkinson Robert J. , Larkin James , Turajlic Samra ,   The CAPTURE Consortium
Published: October 2021

Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.